Tag:

AMRI

Latest Headlines

Latest Headlines

AMRI buys into proteomics to expand its discovery services

Contract drug developer AMRI is expanding its platform to include protein R&D, investing in a market the company expects to boom over the coming years.

AMRI swings to revenue growth amid a transitional year

Contract drug developer AMRI posted a 15% boost in its quarterly revenue, using M&A and manufacturing demand to help wean it off royalty cash.

AMRI eyes a big year after completing another buyout

Contract developer AMRI has closed its $110 million acquisition of drug manufacturer Oso Biopharmaceuticals, its second deal this year and one the company believes will help pad its annual revenue.

AMRI finishes second manufacturing buy in 3 months

AMRI is building up its contract manufacturing operations and has completed a $110 million deal for Oso Biopharmaceuticals Manufacturing to add that company's expertise in complex injectable drug products to its stable.  

AMRI lays out $110M to buy Oso Biopharmaceuticals

AMRI said the Albuquerque, NM-based Oso will expand its capabilities in small-molecule and biologics manufacturing.

AMRI's paying $110M for a bolt-on CMO

In the midst of an ongoing reorganization, contract developer AMRI has made another buy in manufacturing, signing a deal to scoop up CMO OsoBio for $110 million in cash.

AMRI posts flat revenue as transitional year marches on

Contract drug developer AMRI turned in a stagnant revenue quarter, watching profits slip as it prepares to shake off its dependence on royalties and embrace a future in large-scale manufacturing.

AMRI plans to shutter an R&D shop to save cash

Contract drug developer AMRI will close down its Syracuse, NY, facility by midyear, part of an effort to cut costs and realign its business.

AMRI expects its $41M Cedarburg deal to pay off right away

AMRI has wrapped up its $41 million effort to acquire contract manufacturer Cedarburg Pharmaceuticals, and the company says it's in line for an immediate windfall.

AMRI ratchets manufacturing up further with Cedarburg buyout

AMRI saw a big jump in revenues last year as its manufacturing side kicked in additional revenue. Now it wants some more of that action and so is picking up Cedarburg Pharmaceuticals, a specialist in APIs for controlled drugs, in a $41 million deal.